FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324258650> ?p ?o ?g. }

• W4324258650 endingPage "e565" @default.
• W4324258650 startingPage "e556" @default.
• W4324258650 abstract "Clinical practice and diagnostic algorithms often assume that tuberculosis can be ruled out in mycobacteriology-negative individuals whose symptoms improve with a trial-of-antibiotics. We aimed to investigate diagnostic performance, clinical benefit, and antimicrobial resistance using a randomised controlled trial.In this three-arm, individually randomised, open-label, controlled trial, we enrolled Malawian adults (aged ≥18 years) attending primary care who reported being unwell for at least 14 days (including cough) with no immediate indication for hospitalisation at Limbe and Ndirande Health Centres in Blantyre. Participants were randomly allocated (1:1:1) to azithromycin (500 mg taken once per day for 3 days), amoxicillin (1 g taken three times per day for 5 days), or standard of care with no immediate antibiotics, stratified by study site. Sputum at enrolment and day 8 was tested for tuberculosis (microscopy, Xpert MTB/RIF, and culture). The primary efficacy outcome was day 8 specificity (percentage with symptom improvement among mycobacteriology-negative participants), and day 29 clinical outcome (death, hospitalisation, or missed tuberculosis diagnosis) among all randomised participants. This study is registered with ClinicalTrials.gov, NCT03545373.Between Feb 25, 2019, and March 14, 2020, 5825 adults were screened and 1583 (mean age 36 years; 236 [14·9%] HIV positive) were randomly assigned to standard of care (530 participants), azithromycin (527 participants), or amoxicillin (526 participants) groups. Overall, 6·3% (100 of 1583 participants) had positive baseline sputum mycobacteriology. 310 (79·1%) of 392 patients receiving standard of care reported symptom improvement at day 8, compared with 340 (88·7%) of 383 patients receiving azithromycin (adjusted difference 8·6%, 95% CI 3·9-13·3%; p<0·0004) and 346 (89·4%) of 387 receiving amoxicillin (adjusted difference 8·8%, 4·0-13·6%; p=0·0003). The proportion of participants with day 29 composite clinical outcomes was similar between groups (standard of care 1% [7 of 530 participants], azithromycin 1% [6 of 527 participants], amoxicillin 2% [12 of 526 participants]).Routine outpatient trial-of-antibiotics during tuberculosis investigations modestly improved diagnostic specificity for mycobacteriologically confirmed tuberculosis but had no appreciable effect on death, hospitalisation, and missed tuberculosis diagnosis. These results confirm the limited benefit of trial-of-antibiotics, presenting an opportunity for discontinuation of trial-of-antibiotics and improved antimicrobial stewardship during tuberculosis screening, without affecting clinical outcomes.Northern Norway Regional Health Authority (Helse Nord RHF), Commonwealth Scholarship Commission in the UK, Wellcome Trust, UK Medical Research Council, and the UK Department for International Development." @default.
• W4324258650 created "2023-03-15" @default.
• W4324258650 creator A5019225367 @default.
• W4324258650 creator A5024770814 @default.
• W4324258650 creator A5026823919 @default.
• W4324258650 creator A5036267935 @default.
• W4324258650 creator A5039965380 @default.
• W4324258650 creator A5043055797 @default.
• W4324258650 creator A5055927583 @default.
• W4324258650 creator A5060156097 @default.
• W4324258650 creator A5061156103 @default.
• W4324258650 creator A5066263088 @default.
• W4324258650 creator A5074347726 @default.
• W4324258650 creator A5075488953 @default.
• W4324258650 creator A5079122542 @default.
• W4324258650 creator A5083991268 @default.
• W4324258650 date "2023-04-01" @default.
• W4324258650 modified "2023-09-30" @default.
• W4324258650 title "Trial-of-antibiotics to assist tuberculosis diagnosis in symptomatic adults in Malawi (ACT-TB study): a randomised controlled trial" @default.
• W4324258650 cites W126675856 @default.
• W4324258650 cites W1728638204 @default.
• W4324258650 cites W1969657852 @default.
• W4324258650 cites W1981750380 @default.
• W4324258650 cites W1984486655 @default.
• W4324258650 cites W2006761364 @default.
• W4324258650 cites W2007331931 @default.
• W4324258650 cites W2056296793 @default.
• W4324258650 cites W2070563246 @default.
• W4324258650 cites W2100106336 @default.
• W4324258650 cites W2126741462 @default.
• W4324258650 cites W2160479209 @default.
• W4324258650 cites W2167806904 @default.
• W4324258650 cites W2171609823 @default.
• W4324258650 cites W2180752973 @default.
• W4324258650 cites W2207760002 @default.
• W4324258650 cites W2332356363 @default.
• W4324258650 cites W2362799088 @default.
• W4324258650 cites W2748706728 @default.
• W4324258650 cites W2752437548 @default.
• W4324258650 cites W2801473097 @default.
• W4324258650 cites W2889562406 @default.
• W4324258650 cites W2893416956 @default.
• W4324258650 cites W2961153071 @default.
• W4324258650 cites W3013114706 @default.
• W4324258650 cites W3037614970 @default.
• W4324258650 cites W3046316180 @default.
• W4324258650 cites W3213745049 @default.
• W4324258650 cites W4240151307 @default.
• W4324258650 cites W4377077025 @default.
• W4324258650 doi "https://doi.org/10.1016/s2214-109x(23)00052-9" @default.
• W4324258650 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36925176" @default.
• W4324258650 hasPublicationYear "2023" @default.
• W4324258650 type Work @default.
• W4324258650 citedByCount "2" @default.
• W4324258650 countsByYear W43242586502023 @default.
• W4324258650 crossrefType "journal-article" @default.
• W4324258650 hasAuthorship W4324258650A5019225367 @default.
• W4324258650 hasAuthorship W4324258650A5024770814 @default.
• W4324258650 hasAuthorship W4324258650A5026823919 @default.
• W4324258650 hasAuthorship W4324258650A5036267935 @default.
• W4324258650 hasAuthorship W4324258650A5039965380 @default.
• W4324258650 hasAuthorship W4324258650A5043055797 @default.
• W4324258650 hasAuthorship W4324258650A5055927583 @default.
• W4324258650 hasAuthorship W4324258650A5060156097 @default.
• W4324258650 hasAuthorship W4324258650A5061156103 @default.
• W4324258650 hasAuthorship W4324258650A5066263088 @default.
• W4324258650 hasAuthorship W4324258650A5074347726 @default.
• W4324258650 hasAuthorship W4324258650A5075488953 @default.
• W4324258650 hasAuthorship W4324258650A5079122542 @default.
• W4324258650 hasAuthorship W4324258650A5083991268 @default.
• W4324258650 hasBestOaLocation W43242586501 @default.
• W4324258650 hasConcept C126322002 @default.
• W4324258650 hasConcept C142724271 @default.
• W4324258650 hasConcept C168563851 @default.
• W4324258650 hasConcept C187212893 @default.
• W4324258650 hasConcept C2776301714 @default.
• W4324258650 hasConcept C2778907293 @default.
• W4324258650 hasConcept C2779708577 @default.
• W4324258650 hasConcept C2781069245 @default.
• W4324258650 hasConcept C501593827 @default.
• W4324258650 hasConcept C535046627 @default.
• W4324258650 hasConcept C71924100 @default.
• W4324258650 hasConcept C86803240 @default.
• W4324258650 hasConcept C89423630 @default.
• W4324258650 hasConceptScore W4324258650C126322002 @default.
• W4324258650 hasConceptScore W4324258650C142724271 @default.
• W4324258650 hasConceptScore W4324258650C168563851 @default.
• W4324258650 hasConceptScore W4324258650C187212893 @default.
• W4324258650 hasConceptScore W4324258650C2776301714 @default.
• W4324258650 hasConceptScore W4324258650C2778907293 @default.
• W4324258650 hasConceptScore W4324258650C2779708577 @default.
• W4324258650 hasConceptScore W4324258650C2781069245 @default.
• W4324258650 hasConceptScore W4324258650C501593827 @default.
• W4324258650 hasConceptScore W4324258650C535046627 @default.
• W4324258650 hasConceptScore W4324258650C71924100 @default.
• W4324258650 hasConceptScore W4324258650C86803240 @default.
• W4324258650 hasConceptScore W4324258650C89423630 @default.
• W4324258650 hasIssue "4" @default.

• next